Given the evidence for a detrimental effect of the complete suppression of cytokine release in sepsis [20,56,57], compounds that are able to inhibit LPS-induced signaling while maintaining a modest activation of TLR4-mediated responses represent a valuable alternative. The gene discussed is TLR4; the disease is Sepsis.